Navigation Links
Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
Date:12/7/2009

PINE BROOK, N.J., Dec. 7 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, announced today that recent animal efficacy and human safety data from the Company's Anthim® anthrax anti-toxin program were presented at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day conference, December 4, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO )

In a podium presentation entitled "Advanced Development of Anthim® (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalational Anthrax: results of recent safety and efficacy studies," Dr. Leslie Casey, Vice President of Research, presented data from rabbit and primate treatment studies as well as clinical safety studies highlighting the therapeutic potential for Anthim in the treatment of anthrax disease. Using an established non-human primate treatment model, up to 79% of animals treated with a single, intravenous dose of Anthim at the onset of symptoms survived a lethal inhalational challenge with anthrax spores. All animals in this study were bacteremic at time of Anthim treatment.

The Company also reported the results of a previously conducted rabbit treatment study. A single dose of Anthim provided up to 94% survival when administered to rabbits after symptoms of disease were present. The results of these two studies are consistent with previously conducted rabbit and primate studies using Anthim and continue to show the dramatic increase in survival that Anthim can provide.

In a separate dose-escalating human clinical safety study, preliminary results show that Anthim continues to be safe and well-tolerated at doses at or above the anticipated efficacious dose in humans.

Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the continued success of our Anthim program as we move into the final stages of drug development. Anthim consistently provides significant survival benefit in the treatment of anthrax infection and is safe and well-tolerated. Our drug has the potential to deliver considerable therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

This project has been supported with federal funds from BARDA, Department of Health and Human Services (HHS), in conjunction with the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C.

Anthim Background

Anthim has been extensively studied in multiple models of anthrax infection and has consistently prevented death in 70 - 100% of animals treated with a single dose of drug. Anthim shows excellent potential as an effective therapeutic for treatment of people infected or exposed to anthrax spores.

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. To date, Elusys has been awarded a total of $34 million in government funding for advanced development of Anthim. Funding has been received from the NIAID, BARDA, HHS, and the Department of Defense.

About Elusys

Elusys, a private company based in Pine Brook, New Jersey, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.

SOURCE Elusys Therapeutics, Inc.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
2. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
3. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
4. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
6. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
7. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
9. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
10. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
11. Dr. Julian Henley MD Presents BioMatrix Lift
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):